Akcea Therapeutics (NASDAQ:AKCA) Earning Somewhat Favorable Media Coverage, Analysis Finds

Share on StockTwits

News stories about Akcea Therapeutics (NASDAQ:AKCA) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Akcea Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.5816167121511 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Akcea Therapeutics opened at $25.92 on Friday, according to Marketbeat.com. The firm has a market capitalization of $2.19 billion and a PE ratio of -11.57. Akcea Therapeutics has a 1 year low of $8.10 and a 1 year high of $33.99.

Akcea Therapeutics (NASDAQ:AKCA) last posted its quarterly earnings data on Thursday, May 3rd. The company reported ($0.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.07). The company had revenue of $17.11 million for the quarter, compared to analysts’ expectations of $12.12 million. Akcea Therapeutics had a negative net margin of 126.00% and a negative return on equity of 75.90%. The firm’s revenue was up 181.0% on a year-over-year basis. research analysts expect that Akcea Therapeutics will post -1.82 earnings per share for the current year.

Several research analysts have weighed in on AKCA shares. Zacks Investment Research downgraded shares of Akcea Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 9th. Wells Fargo & Co restated a “market perform” rating and set a $20.00 price objective on shares of Akcea Therapeutics in a report on Monday, March 19th. BidaskClub upgraded shares of Akcea Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 24th. Cowen lowered shares of Akcea Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, February 27th. Finally, ValuEngine upgraded shares of Akcea Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Akcea Therapeutics has an average rating of “Hold” and an average price target of $29.25.

In related news, major shareholder Ionis Pharmaceuticals Inc acquired 10,666,666 shares of Akcea Therapeutics stock in a transaction on Tuesday, April 17th. The stock was purchased at an average cost of $18.75 per share, with a total value of $199,999,987.50. Following the purchase, the insider now directly owns 53,447,879 shares in the company, valued at $1,002,147,731.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.88% of the stock is owned by corporate insiders.

About Akcea Therapeutics

Akcea Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy.

Insider Buying and Selling by Quarter for Akcea Therapeutics (NASDAQ:AKCA)

Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply